Altimmune, Inc.
For the period ended Dec 31, 2025. Filed Mar 6, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
16. Subsequent Events
The Company evaluated subsequent events through the issuance date of the financial statements. During January and February 2026, the Company raised $8.2 million in net proceeds through the issuance of 1,874,597 shares of common stock from the Company’s at-the-market offerings program under the November 2025 Agreement.
On January 27, 2026, the Company entered into a securities purchase agreement with a new fundamental institutional investor pursuant to a registered direct offering under the November 2025 Shelf for the purchase and sale of 12,397,920 shares of its common stock and 4,647,534 pre-funded warrants for net proceeds of approximately $70.4
million. The pre-funded warrants were fully exercised on February 13, 2026, resulting in the issuance of 4,647,534 shares of the Company’s common stock.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.